Monday, August 15, 2011
HealthNewsReview.org: Hot Chemotherapy Bath: Patients See Hope, Critics Hold Doubtsies | Holding Health and Medical Journalism Accountable
"Our Review SummaryThis story opens readers' eyes to a debate that flared up before attendees of a recent meeting of the American Society of Clinical Oncology - but a debate that most of us wouldn't know about......"
Note: some media reports reference 'possible' future role for ovarian cancer and therefore this link and again reminders of what is still in research/harms of hype.....
Gene Therapy Cures Adult Leukemia
August 10, 2011
RATING:Somebody at WebMD must take responsibility for a headline that says "cure" after one year's experience in 3 patients. Cure used to be defined in 5 year terms. Is WebMD redefining the term?
Platinum Sensitivity–Related Germline Polymorphism Discovered via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients
This study shows the potential of cell-based, genome-wide approaches to identify germline predictors of treatment outcome and highlights the need for extensive validation in patients to assess their clinical effect.
ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers. ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers, leukemia, and multiple myeloma. ENMD-2076 is currently in a Phase 2 trial for ovarian cancer, and preclinical and clinical activities are ongoing in assessing the compound's applicability for other forms of cancer.